OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Prevention of Alzheimer’s Dementia
Submission Deadline: December 01, 2022 (Open) Submit Now
Jeffrey Fessel, MD, Professor of Clinical Medicine,Emeritus
Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USA
Research Interests: preventing future dementia in elderly persons with currently normal cognition
Carlos Spuch, PhD, Senior Researcher
1. Neuroscience Translational Group. Galicia Sur Health Research Institute.
2. CIBER of Mental Health (CIBERSAM)
Research Interests: Alzheimer disease; Depression; Biomarkers; Anxiety; Schizophrenia; Age-related diseases
About This Topic
Multiple attempts to reverse Alzheimer’s dementia (AD) have, so-far, failed to do so, and nothing on the distant horizon provides any optimism that the goal to do so might be accomplished in the foreseeable future. Therefore, the best and most beneficial approach would be to prevent, in those persons at risk of future AD because their age is >70, the initiation of the cognitive loss that leads eventually to the development of dementia. The aim of this special edition of OBM Geriatrics, is to explore the various, potential approaches that might achieve that prevention.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.